041830 · KOSDAQ · ₩041830 · 인바디
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−36.9% from the high
₩26,200Today: ₩45,700 – ₩47,050₩73,500
Returns
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals describe activity, not recommendations. Not financial advice.
Estimated leveraged-ETF rebalance on Oct 28: buy ₩1B at the close (35.7% of 20-day average trading value)
On its 15 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 12.6% of trading value and pointed the same way 11 of 15 times.
Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.
Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.
Estimate based on ETF size and daily moves; actual trades may differ.
Held by 11 funds.
Estimated from the funds' index or underlying stock.
InBody (인바디, KRX: 041830) is listed on KOSDAQ, in the Medical & precision devices sector. InBody is a Seoul-headquartered Korean maker of medical devices, operating through 18 subsidiaries, 4 in Korea and 14 overseas. Its shares closed at ₩46,400 on Oct 28, 2026, up 0.98% on the day, giving it a market value of ₩626B.
InBody is a Seoul-headquartered Korean maker of medical devices, operating through 18 subsidiaries, 4 in Korea and 14 overseas. Its main products are body composition analyzers, automatic blood pressure monitors, home-use body composition analyzers, height and weight measurers, and management software. It sells through direct sales and domestic and overseas distributor networks to hospitals and clinics, fitness centers, military units, schools and government offices, companies, and individual consumers. Overseas sales account for most of its revenue, with the United States as its largest market.
Written by AI from the company's latest annual report.
Predicted impact: Low
Celebrity health rumor with a minor investment in a related company; no material size.
Predicted impact: Low
Small Series A raise of 3B won by a startup with InBody as investor.
Predicted impact: Low· Actual: +7.3% vs sector, volume 1.0× normal (5 trading days)
Feature article on demand for body composition analyzers; no company-specific financial event.
Titles in Korean until English translations are added.
Also known as: InBody / 인바디 / 041830 / KRX:041830
Source: KRX statistical information